Dr. Bacharach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
104 Lynch Creek Way
Suite 15
Petaluma, CA 94954Phone+1 707-762-3573Fax+1 707-762-6873
Education & Training
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Ophthalmology, 1989 - 1992
- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1988 - 1989
- Drexel University College of MedicineClass of 1988
Certifications & Licensure
- CA State Medical License 1992 - 2026
- PA State Medical License 1990 - 1992
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Start of enrollment: 2008 Jun 01
- Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery Start of enrollment: 2011 Dec 22
- Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery Start of enrollment: 2012 Jan 16
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsNegative Pressure Application via a Multi-Pressure Dial to Lower IOP in Patients with Suspected Glaucoma or Open Angle Glaucoma.Thomas W Samuelson, Tanner J Ferguson, Jacob W Brubaker, Jason Bacharach, Mark J Gallardo
Journal of Glaucoma. 2023-08-01 - 98 citationsDouble-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.Jason Bacharach, Harvey Dubiner, Brian Levy, Casey Kopczynski, Gary D. Novack
Ophthalmology. 2015-02-01 - 72 citationsA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalm...Bret A Hughes, Jason Bacharach, E. Randy Craven, Martin B Kaback, Sushanta Mallick
Journal of Glaucoma. 2005-10-01
Authored Content
- Proper DropperJanuary 2024
- Real-World Data Show Additive Effects of NetarsudilNovember 2020
Press Mentions
- https://www.prnewswire.com/news-releases/Iyuzeh-Latanoprost-Ophthalmic-Solution-0-005-the-First-and-Only-Preservative-Free-Latanoprost-Ophthalmic-Solution-Demonstrated-Similar-Iop-Lowering-Efficacy-with-a-favorable-Safety-Profile-When-Compared-to-Xalatan-in-Patien-301761686.htmlMarch 3rd, 2023
- Real-World Data Show Additive Effects of NetarsudilNovember 3rd, 2020
- Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive SurgeryApril 11th, 2018
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: